Central nervous system - commissioning policies
Please click on the links below to access the commissioning policies. The associated Equality Impact Assessments, if currently available, are accessible here.
The CCGs’ position on the implementation of policies affecting patient referral can be found here.
- Aripiprazole long-acting (depot) injection for schizophrenia
- Botulinum Toxin A for the management of blepharospasm
Patients diagnosed with blepharospasm should be advised to check with the Driver and Vehicle Licensing Agency (DVLA) the requirements for notification and assessment with regard to continuing their licence to drive.
- Botulinum Toxin A for the management of hemifacial spasm
- Brivaracetam for the management of epilepsy
- Capsaicin (8%) patch (Qutenza®) for the treatment of neuropathic pain
- Guanfacine prolonged-release capsules (Intuniv®) for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents
- Lisdexamfetamine for the management of attention deficit hyperactivity disorder in children and adolescents
- Olanzapine long-acting (depot) injection for schizophrenia
- Paliperidone long-acting (depot) injection for schizophrenia
- Safinamide for mid-to-late stage fluctuating Parkinson’s disease
- Sativex® oromucosal spray for treatment of spasticity in multiple sclerosis
- Skin surface applied functional electrical stimulation for an orthotic effect to correct foot drop of central neurological origin
- Sodium oxybate for narcolepsy with cataplexy
Please note: Some commissioning policies approved by the previous commissioning organisations have not been reviewed and updated yet. However they are still applicable for the local population and can be accessed here.